What is the role of inhaled loxapine in the treatment of bipolar affective disorder (manic-depressive illness)?

Updated: May 30, 2019
  • Author: Stephen Soreff, MD; Chief Editor: Glen L Xiong, MD  more...
  • Print

Inhaled loxapine (Adasuve) is the first noninjectable therapy approved by the FDA to treat acute agitation associated with schizophrenia and bipolar disorder type I (BPI). The FDA approval was based on 2 phase III studies of 658 individuals; statistically significant reductions in agitation were apparent starting 10 minutes following administration compared with placebo, and these effects were sustained at 2 hours. [84, 85]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!